Investigational drug · Phase 2
L608
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Systemic Sclerosis.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "L608"
First trial start
2027
Feb 1, 2027
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "L608", any sponsor or status.
Conditions studied
As listed on its trial records.
- Systemic Sclerosis
Largest trials
Live from ClinicalTrials.gov: studies naming "L608" as an intervention, largest first.
Pharmosa Biopharm Inc.Industry
NCT05938946 · 64 participants · Start Aug 30, 2023 · Primary completion Sep 2, 2024
Drug: L608 Inhalation Solution; Placebo solution · For: Pulmonary Arterial Hypertension
Sites: Adelaide, Australia
Pharmosa Biopharm Inc.Industry
NCT06429930 · 40 participants (planned) · Start Apr 11, 2025 · Primary completion Dec 31, 2026
Drug: L608 Liposomal inhalation suspension; Placebo Solution · For: Healthy Adult Participants
Sites: Christchurch, New Zealand
- Efficacy and Safety Study of L608 in Patients With Systemic Sclerosis-associated Digital UlcersNot yet recruiting
Pharmosa Biopharm Inc.Industry
NCT07925619 · 40 participants (planned) · Start Feb 1, 2027 · Primary completion Dec 31, 2028
Drug: L608; Placebo · For: Systemic Sclerosis
Newest research
PubMed records naming it or its code names, newest first.
- Corrigendum for Kanmani et al., volume 324, 2023, p. L596-L608.
· Am J Physiol Lung Cell Mol Physiol 2025
- Structure-Informed Insights into Catalytic Mechanism and Multidomain Collaboration in α-Agarase CmAga.
You Y, Gan BK, Luo M, et al. · J Agric Food Chem 2025
- Molecular dynamics study of talin-vinculin binding.
Lee SE, Chunsrivirot S, Kamm RD, et al. · Biophys J 2008
Also in development for Systemic Sclerosis
- AZD0120GC012FPhase 39 trials
AstraZeneca · Newly Diagnosed Multiple Myeloma (NDMM), Relapsed AL Amyloidosis, Refractory AL Amyloidosis
- Rese-celCABA-201Phase 34 trials
Cabaletta Bio · Pemphigus Vulgaris, Systemic Sclerosis, Scleroderma
- Zola-celBMS-986353, CC-97540Phase 33 trials
Bristol Myers Squibb · Systemic Sclerosis, Lupus Erythematosus, Systemic, Lupus Nephritis
- ABBV-722Phase 32 trials
AbbVie · Rheumatoid Arthritis, Systemic Sclerosis
- UC-MSCRY_SW01 cell, Human umbilical cord mesenchymal stem cellsPhase 28 trials
Jiangsu Renocell Biotech Company · Acute Respiratory Distress Syndrome, Lupus Nephritis, Spinocerebellar Ataxia Type 1
- NKX019Phase 22 trials
Nkarta, Inc. · Lupus Nephritis, Primary Membranous Nephropathy, Systemic Sclerosis
- PF-08154225Phase 21 trial
Pfizer · Systemic Lupus Erythematosus, Rheumatoid Arthritis, Idiopathic Inflammatory Myositis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.